SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as record Super Bowl betting volume is anticipated, with community discussion intensely focused on how burgeoning prediction markets, operating under different regulatory frameworks, will impact its future profitability and market share amidst its own expansion into the evolving sector ahead of its impending earnings report.

WorldFinancial

WorldFinancial (WLFI) is trending amid a U.S. House probe into a significant investment deal, fueling polarized community discussion over its legitimacy as a Trump-linked project with ambitions in stablecoins and Real World Asset tokenization.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as the community hotly debates the implications of the company's abrupt halt of its compounded weight-loss pill due to intense regulatory scrutiny, with bulls anticipating a short squeeze now that legal overhang is removed and bears expressing deep concern over management's decision-making and potential impact on growth.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors await its upcoming earnings report and the highly anticipated, yet debated, POSCO partnership, with community sentiment split between expectations of a significant upside from strong HRC prices and the termination of a costly slab contract, versus concerns over recent equity dilution and historical underperformance within the steel sector.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is buzzing after hitting a $1 trillion market cap and joining the Nasdaq-100, with its strategic AI partnerships and expanding e-commerce driving a narrative of robust, tech-driven retail transformation that has the community actively discussing its surprising strength.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors eagerly await its BLA resubmission in February, a key step validated by the FDA's request for the full HOPE-3 clinical study report without additional trials. This development reinforces confidence in its Duchenne muscular dystrophy therapy and promising exosome platform amidst discussions of institutional interest.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to significant Super Bowl exposure for its Briumvi MS treatment, featuring Christina Applegate, a campaign that the community views as a "huge win" for raising awareness and highlighting the drug's best-in-class efficacy amid concerns over competitors like Roche's Fenebrutinib. The widespread discussion emphasizes Briumvi's strong safety profile and potential to attract new patients, fueling optimism for its market position.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending after the FDA accepted its New Drug Application for CTx-1301 and set a May 2026 PDUFA date for its innovative once-daily ADHD treatment. The community is actively discussing the stock's low market cap and tiny float, anticipating potential US patent news and significant upside, including possible buyouts.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co.

Becton, Dickinson And Co.

Becton Dickinson is trending as investors anticipate its Q1 earnings, with community discussions weighing expected declines against broad product demand and significant corporate actions like the pending Waters Corp. spin-off. Recent innovations in AI-driven flow cytometry, expanded biologics partnerships, and new medical device approvals are also driving conversation around the stock's current valuation and future growth.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is gaining significant attention due to its critical role in cutting-edge defense contracts for AR systems like Anduril's EagleEye and surging demand for its space and AI infrastructure optics, with community discussion highlighting its exceptionally tight float and strong insider ownership as key bullish factors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Northland Securities Comments on Genius Sports Q2 Earnings

Genius Sports Limited (NYSE:GENI - Free Report) - Research analysts at Northland Securities issued their Q2 2026 earnings per share (EPS) estimates for shares of Genius Sports in a research note...

Citigroup Has Lowered Expectations for Genius Sports (NYSE:GENI) Stock Price

Citigroup dropped their target price on Genius Sports from $16.00 to $13.00 and set a "buy" rating on the stock in a research report on Friday...

Guggenheim Has Lowered Expectations for Genius Sports (NYSE:GENI) Stock Price

Guggenheim lowered their target price on shares of Genius Sports from $17.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday...

Genius Sports' (GENI) "Buy" Rating Reaffirmed at BTIG Research

BTIG Research reiterated a "buy" rating and issued a $16.00 price objective on shares of Genius Sports in a research note on Friday...

Genius Sports Calls Legend Deal Transformational, Sees $1.1B Revenue Run Rate in 2026

Genius Sports (NYSE:GENI) management used a company call to detail its planned acquisition of Legend, describing the deal as a transformational transaction that accelerates the company's strategy to...

<ul class="summary-bullets"><li>For Genius Sports, the transaction is expected to be immediately accretive to group adjusted core profit and free cash flow conversion.&nbsp;</li><li>Genius Sports said its prelim group revenue for FY25 is of $669 million, reflecting 31% year-on-year growth.</li><li>It also expects to generate group revenue of approximately $810-820 million in FY26.</li></ul>Genius Sports (<a href="https://stocktwits.com/symbol/GENI">GENI</a>) shares plunged on Thursday after it announced it has entered into a definitive agreement to acquire Legend, a global, digital sports and gaming media network.Shares plunged 26.5% to $6.28 at the time of writing and garnered retail chatter around the deal.<h2 class="st-heading-2">Deal Details</h2>Genius Sports said it is acquiring Legend in a transaction valued at up to $1.2 billion, including $900 million payable at closing and an earnout of up to $300 million.For Genius Sports, the transaction is expected to be immediately accretive to group adjusted core profit margins and free cash flow conversion while maintaining at least 20% group revenue compound annual growth rate (CAGR) through 2028.&nbsp;On a 2026 annualized pro forma basis; after giving effect to the acquisition, the combination is expected to position Genius to achieve approximately $1.1 billion in group revenue, $320-330 million in group adjusted core profit with approximately 50% free cash flow conversion.“This deal accelerates our strategic and financial objectives, supercharges fan monetization, and builds a fully integrated sports and gaming media network,” said Mark Locke, CEO of Genius Sports.<h2 class="st-heading-2">Prelim FY25 Earnings And FY26Outlook</h2>The company on Thursday also reported its preliminary unaudited financial results for the fiscal year ended December 31, 2025. It said its prelim group revenue is $669 million, reflecting 31% year-on-year growth.Genius Sports also expects to generate group revenue of approximately $810-820 million, and group adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of approximately $180-190 million in 2026 on a standalone basis.&nbsp;Group Revenue of $1.6 billion, representing approximately 21% compound annual growth rate (CAGR) from 2026 to 2028, as the acquisition and integration of Legend will also set a higher performance benchmark for 2028, it said in a statement.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GENI trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user on Stocktwits opined that they are not sure that GENI needed to inject this risk as its business was doing well.&nbsp;<stembedurl>https://stocktwits.com/Windy007/message/644135227</stembedurl>Another user said they were not expecting the company to strike a more than $1billion worth deal.<stembedurl>https://stocktwits.com/Jblack500/message/644132457</stembedurl>Shares in the company have fallen 34% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-coin-stock-down-today/cZbZWG7R4Vz">Why is COIN Stock Falling More Than 8% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Shares of GENI plunged 26.5% to $6.28 at the time of writing and garnered retail chatter around the deal.

Genius Sports’ Stock Is Down 26% Today – Why Is Retail Wary?

 Genius Sports said it is acquiring Legend in a transaction valued at up to $1.2 billion, including $900 million payable at closing and an earnout of up to $300 million.

Equity

Genius Sports (NYSE:GENI) Sees Strong Trading Volume - Should You Buy?

Genius Sports (NYSE:GENI) Sees Strong Trading Volume - Here's What Happened...

Genius Sports Enters into Definitive Agreement to Acquire Legend, Creating a Digital Sports and Gaming Media Powerhouse

Genius Sports Limited (NYSE: GENI) (Genius Sports) today announced it has entered into a definitive agreement (Agreement) to acquire Legend, a global, digital sports and gaming media network built to...

Genius Sports (NYSE:GENI) Hits New 1-Year Low - Time to Sell?

Genius Sports (NYSE:GENI) Sets New 52-Week Low - Here's What Happened...

New York State Common Retirement Fund Buys 781,411 Shares of Genius Sports Limited $GENI

New York State Common Retirement Fund increased its stake in shares of Genius Sports Limited (NYSE:GENI - Free Report) by 395.5% during the 3rd quarter, according to the company in its most recent...

Genius Sports Ltd. engages in the provision of scalable, technology-led products and services to the sports, sports betting, and sports media industries. It also involves in Sports League, which offers technology infrastructure for the collection, integration, and distribution of live data; Sportsbooks, which includes collection of live sports data, odds making, risk management and player marketing; and Sports Media, which provides a range of online marketing and fan engagement tools. The company was founded by Mark Adrian Locke in 2000 and is headquartered in London, United Kingdom.

Genius Sports Limited

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Stocktwits Polls

The stock plunged dramatically following the controversial $1.2 billion acquisition of Legend, sparking widespread investor concern over debt and perceived overpayment.

There's growing enthusiasm for Genius Sports' significant upside in prediction markets, fueled by discussions around new legislation and the NFL's potential embrace of the sector.

Shareholders are questioning CEO Mark Locke's leadership and the strategic rationale behind the large Legend acquisition amidst intense criticism of its impact on the stock.

GENI
Genius Sports Limited

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GENI News

GENIGenius Sports Limited